Iris Kuss, MD, of Bayer HealthCare, Leverkusen, Germany, provides an overview of the ARAMIS study (NCT02200614), which tested the safety and efficacy of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC). Dr Kuss highlights the promising secondary and patient-relevant endpoint data of darolutamide, as well as the drug’s promising safety profile. This video was filmed at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.